Orforglipron

≥99% HPLCCOA per batchCold-chain shippedIn-house synthesisResearch use only · not for human consumption

Price range: $74.99 through $119.99

Independently verified Tested by IRZC Laboratories Batch NHV26-M2485 · Purity 99.37 % HPLC · Issued 4 Aug 2026 · Cert COA-2MYD-60HK-XVerify at IRZCVerifyScan to verify

An oral, non-peptide, small-molecule GLP-1 receptor agonist — the first of its class to receive FDA approval (March 2026) for type 2 diabetes and obesity without food restrictions.

FormulaC48H48F2N10O5
Mol. weight882.97 g/mol
FormLyophilised powder
0 People watching this product now!
SKU: PEP-064 Category:

Molecular & analytical data

Verified chemistry and third-party reference identifiers for this compound.

Amino acid sequenceNon-peptide small molecule (not a peptide sequence); IUPAC: 3-((1S,2S)-1-(5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-3-(3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2-oxo-2,3-dihydro-1H-imidazol-1-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-1H-indol-1-yl)-2-methylcyclopropyl)-1,2,4-oxadiazol-5(4H)-one
Molecular formulaC48H48F2N10O5
Molecular weight882.97 g/mol
CAS number2212020-52-3
Purity standard≥99%
Half-life29–49 hours (once-daily dosing supported)
BioavailabilityOral bioavailability ~77–79% (absolute bioavailability Phase 1 single dose); food-independent absorption
Origin / sourceSynthetic small molecule; non-peptide; designed by Eli Lilly medicinal chemistry; produced by total organic synthesis
Year discovered2020 (first in human Phase 1); FDA approval April 2026

Reconstitution calculator

Concentration, volume per draw, and the graduation it measures to. Open the full bench calculator with this vial loaded →

Concentration— mg/mL— mcg per unit
—Draw tounits on a U-100 syringe
—Volume / drawmL
—Complete drawsper vial

—

A U-100 insulin syringe reads 100 units per 1 mL. Figures describe the contents of a vial for laboratory handling reference only and are not dosing guidance.

Quality & verification

Every batch is characterised before release and ships with documentation.

≥99%HPLC purity
882.97 g/molMolecular weight
MS + HPLCIdentity & purity assay
Third-party testedBatches are tested by IRZC Laboratories — independent HPLC + mass-spec confirms identity and purity against that product’s release specification.
Batch-matched COAA certificate of analysis is issued per batch and matched to your vial’s lot number.
Cold-chain fulfilmentLyophilised product is packed with insulated, temperature-controlled shipping.
Controlled synthesisProduced under documented, reproducible in-house processes with lot traceability.

Storage & handling

Keep the peptide stable from delivery through reconstitution.

1
On arrivalStore the sealed, lyophilised vial frozen at −20°C, protected from light and moisture.
2
ReconstitutionAdd bacteriostatic water down the vial wall; swirl gently — do not shake. Use the calculator above to plan volume.
3
After mixingRefrigerate the reconstituted solution at 2–8°C and use within the stability window below.
4
HandlingWork in a clean area, wipe the stopper with alcohol, and avoid repeated freeze–thaw cycles.
Manufacturer storage note

Room temperature storage (no refrigeration required — significant advantage over injectable GLP-1s)

Description

Orforglipron (LY-3502970, brand name Foundayo) is a novel, first-in-class oral small-molecule GLP-1 receptor agonist developed by Eli Lilly and Company. Unlike all previous GLP-1 receptor agonists (which are peptides requiring subcutaneous injection), orforglipron is a non-peptide molecule with oral bioavailability that does not require co-administration with food or water restrictions, distinguishing it from semaglutide oral (Rybelsus), which requires specific fasting conditions. Orforglipron acts as a partial agonist at the GLP-1 receptor, activating cyclic AMP (cAMP) signaling to stimulate insulin secretion, suppress glucagon, slow gastric emptying, and reduce food intake through central satiety mechanisms. Phase 3 clinical trials demonstrated body weight reductions of approximately 7–10% in adults with type 2 diabetes and up to 9–16% in adults with obesity, with favorable tolerability. FDA approved orforglipron under the brand name Foundayo in March 2026 for both type 2 diabetes management and chronic weight management — representing a transformative step toward accessible oral GLP-1 therapy. Its oral formulation eliminates injection barriers and may significantly expand GLP-1 therapy access.

Certificates of Analysis

Certificates of Analysis

Every batch of this peptide is tested before release. Find the batch number printed on your vial and verify or download its certificate.

Batch #IssuedPurityCertificate
NHV26-M2485
COA-2MYD-60HK-X
04 Aug 202699.37 % HPLCVerify at IRZC ↗

“Verify at IRZC” opens the laboratory’s own record for that certificate, on their site. Looking for an older batch we haven’t published? Email [email protected] with the batch number from your vial — we keep all certificates for 7 years.

Research & Literature
Reported in research literature — not usage guidance.

The information below summarises published preclinical and clinical research for scientific reference. NHOV products are sold strictly for laboratory research use only. Nothing here is medical advice, a recommendation, or an instruction for use in humans or animals.

Mechanism of action

Partial agonist at GLP-1 receptor (GLP1R); activates Gs-cAMP-PKA pathway; stimulates glucose-dependent insulin secretion from beta cells; suppresses glucagon from alpha cells; delays gastric emptying; reduces food intake via central hypothalamic GLP-1R activation; oral bioavailability due to small-molecule (non-peptide) structure

Primary uses / indications

Obesity/chronic weight management (FDA approved 2026); investigational: type 2 diabetes mellitus, NASH, cardiovascular risk reduction

Typical dosage (reported)

Per the approved FOUNDAYO label: tablets are supplied in 0.8, 2.5, 5.5, 9, 14.5 and 17.2 mg strengths, with a labelled starting dosage of 0.8 mg once daily and a maximum labelled dosage of 17.2 mg once daily

Cycle duration (reported)

Ongoing/indefinite (chronic disease management)

Administration route

Oral tablet (once daily)

Side effects (reported)

Nausea, vomiting, diarrhea, constipation, decreased appetite, abdominal discomfort; generally well tolerated; hypoglycemia (low risk as monotherapy)

Contraindications

Hypersensitivity to orforglipron; personal/family history of MEN2 or medullary thyroid carcinoma; pregnancy

Drug interactions

CYP3A4 substrate (moderate); potential interactions with strong CYP3A4 inhibitors/inducers; oral absorption not affected by food or water; no drug-drug interaction with common cardiovascular medications identified in trials

Reviews (0)
0 reviews
0
0
0
0
0

There are no reviews yet.

Be the first to review “Orforglipron”

Your email address will not be published. Required fields are marked *

You have to be logged in to be able to add photos to your review.

Specifications

Identity

Full name / brand namesOrforglipron; LY-3502970; OWL-833; Foundayo
CategoryGLP-1 Receptor Agonists
SubcategoryOral Small-Molecule GLP-1 Agonist
Origin / sourceSynthetic small molecule; non-peptide; designed by Eli Lilly medicinal chemistry; produced by total organic synthesis
Year discovered2020 (first in human Phase 1); FDA approval April 2026

Chemistry

Amino acid sequenceNon-peptide small molecule (not a peptide sequence); IUPAC: 3-((1S,2S)-1-(5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-3-(3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2-oxo-2,3-dihydro-1H-imidazol-1-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-1H-indol-1-yl)-2-methylcyclopropyl)-1,2,4-oxadiazol-5(4H)-one
Molecular formulaC48H48F2N10O5
Molecular weight882.97 g/mol
CAS number2212020-52-3
PubChem CIDCID 137319706 ↗
Purity standard≥99%

Pharmacokinetics

Half-life29–49 hours (once-daily dosing supported)
BioavailabilityOral bioavailability ~77–79% (absolute bioavailability Phase 1 single dose); food-independent absorption

Regulatory & research status

FDA statusFDA approved (Foundayo, 1 April 2026) for chronic weight management in adults with obesity, or with overweight and at least one weight-related comorbid condition; not approved for type 2 diabetes
Prescription requiredYes (prescription required)
Research statusFDA approved (2026)
Clinical trialsNCT05869903 (ATTAIN-1, Phase 3 obesity); NCT05971940 (ACHIEVE-1, Phase 3 T2D)

References

1. Frias JP et al. Orforglipron efficacy and safety in type 2 diabetes: phase 2 dose-response study. Lancet. 2023;402(10400):472-483. doi:10.1016/S0140-6736(23)01302-8. 2. Pratt EJ et al. Orforglipron (LY3502970), a novel oral non-peptide GLP-1RA: Phase 1a study in healthy participants. Diabetes Obes Metab. 2023;25(10):2808-2816. doi:10.1111/dom.15184. 3. Kansakar U et al. Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes. Int J Mol Sci. 2026;27(3):1409. doi:10.3390/ijms27031409.

Frequently asked questions

What is Orforglipron?
An oral, non-peptide, small-molecule GLP-1 receptor agonist — the first of its class to receive FDA approval (April 2026), for chronic weight management, and taken once daily with or without food.
How does Orforglipron work?
Reported in the research literature: Partial agonist at GLP-1 receptor (GLP1R); activates Gs-cAMP-PKA pathway; stimulates glucose-dependent insulin secretion from beta cells; suppresses glucagon from alpha cells; delays gastric emptying; reduces food intake via central hypothalamic GLP-1R activation; oral bioavailability due to small-m…
What Orforglipron dosage is used in research?
For laboratory research reference only, not usage guidance: Per the approved FOUNDAYO label: tablets are supplied in 0.8, 2.5, 5.5, 9, 14.5 and 17.2 mg strengths, with a labelled starting dosage of 0.8 mg once daily and a maximum labelled dosage of 17.2 mg once daily
What is the half-life of Orforglipron?
The reported biological half-life of Orforglipron is approximately 29–49 hours (once-daily dosing supported).
How should Orforglipron be stored and reconstituted?
NHOV ships Orforglipron as a lyophilised powder. Store unopened vials at −20 °C. Reconstitute with bacteriostatic water; once reconstituted, refrigerate at 2–8 °C, protect from light, and use within the bacteriostatic-water shelf window. Use the NHOV reconstitution calculator to find the exact volume for your target concentration.
What purity is NHOV's Orforglipron?
NHOV Orforglipron is released against a specification of ≥99%, verified by HPLC with mass-spectrometry identity confirmation, and ships with a batch-specific Certificate of Analysis (COA) matched to the vial's lot number.
Is Orforglipron approved for human use?
No. Orforglipron is sold strictly for laboratory and scientific research use only. It is not for human or veterinary consumption and is not approved as a drug.